Infant With SARS-CoV-2 Infection Causing Severe Lung Disease Treated With Remdesivir
Infant With SARS-CoV-2 Infection Causing Severe Lung Disease Treated With Remdesivir
复制标题
DOI：
10.1542/peds.2020-1701
复制
发表时间：
2020-09-01
期刊：
影响因子：
8
通讯作者：
Bamford, Alasdair
中科院分区：
文献类型：
--
作者：
Frauenfelder, Claire;Brierley, Joe;Bamford, Alasdair
我们描述的情况下，婴儿谁开发了严重的肺部SARS-CoV-2感染，在第五周的生活和治疗remdesivir。我们描述了一个前早产儿出现严重急性呼吸综合征冠状病毒2感染的第五周的生活。在目前的报告中，研究人员指出，急性症状性严重急性呼吸综合征冠状病毒2型感染相对罕见，比成人严重得多。该病例强调，感染可能与婴幼儿危及生命的肺部疾病有关，感染可能遵循与成人相似的病程。我们提供了关于在幼儿中使用新型抗病毒药物remdesivir的第一批数据，以及多学科临床团队和生物伦理委员会加速批准同情获得该药物的创新方法。
We describe the case of an infant who developed severe pulmonary SARS-CoV-2 infection in the fifth week of life and was treated with remdesivir. We describe an ex-premature infant presenting with severe acute respiratory syndrome coronavirus 2 infection in the fifth week of life. In current reports, researchers indicate that acute symptomatic severe acute respiratory syndrome coronavirus 2 infection is relatively rare and much less severe than in adults. This case highlights that infection can be associated with life-threatening pulmonary disease in young infants and that infection can follow a similar disease course to that described in adults. We provide first data on the use of the novel antiviral remdesivir in a young child and an innovative approach to expedited approval from a multidisciplinary clinical team and bioethics committee for compassionate access to the drug.